Turnkey, high-end life sciences space remains in high demand in New Jersey, creating an opportunity for owners of the state’s few remaining legacy pharmaceutical campuses or those that can find other ways to create new space without building speculatively.
On the money
I’ve spent a decade watching Devco tackle some of the state’s largest, most ambitious redevelopment projects with complex capital stacks and broad coalitions of stakeholders. It’s a topic that we feature in this month’s cover story, which follows a year in which the organization broke ground on more than $1.5 billion worth of development. That makes it all the more timely for us to highlight an operation that is seemingly unlike any other developer in New Jersey.